{"name":"BIOFRONTERA","slug":"biofrontera","ticker":"","exchange":"","domain":"biofrontera.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BF-200 ALA 1%","genericName":"BF-200 ALA 1%","slug":"bf-200-ala-1","indication":"Actinic keratosis","status":"phase_2"},{"name":"BF-200 ALA 10%","genericName":"BF-200 ALA 10%","slug":"bf-200-ala-10","indication":"Actinic keratosis (field treatment)","status":"phase_2"},{"name":"Placebo to BF-200 ALA gel","genericName":"Placebo to BF-200 ALA gel","slug":"placebo-to-bf-200-ala-gel","indication":"Actinic keratosis (field treatment)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BF-200 ALA 3%","genericName":"BF-200 ALA 3%","slug":"bf-200-ala-3","indication":"Actinic keratosis","status":"phase_2"}]}],"pipeline":[{"name":"BF-200 ALA 1%","genericName":"BF-200 ALA 1%","slug":"bf-200-ala-1","phase":"phase_2","mechanism":"BF-200 ALA 1% is a topical photosensitizer that, when activated by light, generates reactive oxygen species to induce cell death in targeted tissues.","indications":["Actinic keratosis","Superficial basal cell carcinoma"],"catalyst":""},{"name":"BF-200 ALA 10%","genericName":"BF-200 ALA 10%","slug":"bf-200-ala-10","phase":"phase_2","mechanism":"BF-200 ALA is a topical 5-aminolevulinic acid (ALA) formulation that generates reactive oxygen species upon light activation to destroy abnormal skin cells.","indications":["Actinic keratosis (field treatment)","Non-melanoma skin cancer precursor lesions"],"catalyst":""},{"name":"BF-200 ALA 3%","genericName":"BF-200 ALA 3%","slug":"bf-200-ala-3","phase":"phase_2","mechanism":"BF-200 ALA 3% is a topical cream used to treat actinic keratosis.","indications":["Actinic keratosis"],"catalyst":""},{"name":"Placebo to BF-200 ALA gel","genericName":"Placebo to BF-200 ALA gel","slug":"placebo-to-bf-200-ala-gel","phase":"phase_3","mechanism":"BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells.","indications":["Actinic keratosis (field treatment)","Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}